Evidence map›Paper›PMID 34370064›Full record

Trial reportPsychopharmacology2021

Functional connectivity and cognitive changes after donepezil treatment in healthy participants.

P Péran, A S Salabert, T Dondaine, X Leclerc, H Gros-Dagnac, J-P Ranjeva, R Lopes, L Lanteaume, O Blin, C Thalamas and 3 more

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Psychopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. 5-HTBiological psychiatry. Cognitive neuroscience and neuroimaging · 2023
    Trial
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 2 countries.

P PéranToulouse NeuroImaging Center (ToNIC), Université de Toulouse, INSERM, UPS, 31024, Toulouse Cedex 3, France. patrice.peran@inserm.fr.
A S SalabertToulouse NeuroImaging Center (ToNIC), Université de Toulouse, INSERM, UPS, 31024, Toulouse Cedex 3, France.
T DondaineDegenerative & Vascular Cognitive Disorders Research Unit, INSERM-Lille University-Lille University Hospital, Lille, France.
X LeclercDegenerative & Vascular Cognitive Disorders Research Unit, INSERM-Lille University-Lille University Hospital, Lille, France.
H Gros-DagnacToulouse NeuroImaging Center (ToNIC), Université de Toulouse, INSERM, UPS, 31024, Toulouse Cedex 3, France.
J-P RanjevaCentre for Metabolic Exploration by Magnetic Resonance (CEMEREM), Aix-Marseille University-CNRS-CRMBM-Timone University Hospital, Marseille, France.
R LopesDegenerative & Vascular Cognitive Disorders Research Unit, INSERM-Lille University-Lille University Hospital, Lille, France.
L LanteaumeCentre for Metabolic Exploration by Magnetic Resonance (CEMEREM), Aix-Marseille University-CNRS-CRMBM-Timone University Hospital, Marseille, France.
O BlinCentre for Metabolic Exploration by Magnetic Resonance (CEMEREM), Aix-Marseille University-CNRS-CRMBM-Timone University Hospital, Marseille, France.
C ThalamasClinical Investigation Center (CIC1436), Toulouse, France.
R BordetDegenerative & Vascular Cognitive Disorders Research Unit, INSERM-Lille University-Lille University Hospital, Lille, France.
P PayouxToulouse NeuroImaging Center (ToNIC), Université de Toulouse, INSERM, UPS, 31024, Toulouse Cedex 3, France.
PharmaCog Consortium
Université de Lille · FRImaging, Brain, and Neuropsychiatry · FRCentre Hospitalier Universitaire de Toulouse · FRCentre National de la Recherche Scientifique · FRImaging Center · USInserm · FRInstitut de Neurosciences des Systèmes · FRLille Neurosciences & CognitionUniversité Toulouse III - Paul Sabatier · FR

Funding

FP7 Ideas: European Research Council 115009
6 · The paper itself

Abstract

rationaleDonepezil is a potent, noncompetitive, reversible, clinically effective acetylcholinesterase inhibitor. The effects of this drug on healthy brains have seldom been investigated.

objectivesThe primary objective of the present study was to identify possible functional connectivity markers of the effect of donepezil in healthy young adult volunteers.

methodsThe study had a double-blind, randomized, crossover design. 30 healthy adult volunteers underwent resting-state MRI scans during 15 days of donepezil or placebo treatment, in accordance with the design.

resultsResults showed significant differences in intrinsic functional connectivity between donepezil and placebo, mainly in the right executive control network (RECN). More specifically, we found a decrease in the connectivity of the right inferior parietal node with other RECN nodes. Analysis using the cingulate cortex and parahippocampal regions as seeds also revealed complex modulation of functional connectivity in the donepezil condition.

conclusionsIn conclusion, donepezil treatment for 15 days may result in reorganization of resting-state networks, compared with placebo.

Indexed as

AcetylcholinesteraseMagnetic Resonance ImagingCognitionDonepezilDouble-Blind MethodHealthy VolunteersHumansYoung AdultAcetylcholinesteraseDonepezilCognitive modulationDonepezilFunctional connectivityResting state MRI

Identifiers

PMID34370064
OpenAlexW3193020704

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.